Pharmacokinetics Study of Nimotuzumab Single-dose and Multiple-dose in Combination With Irinotecan in Patients With Solid Tumors
Latest Information Update: 14 Jan 2020
Price :
$35 *
At a glance
- Drugs Nimotuzumab (Primary) ; Irinotecan
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Biotech Pharmaceutical
- 18 Aug 2015 Planned End Date changed from 1 Jun 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 23 Mar 2015 New trial record